Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals

Despite the overwhelming success of mRNA-based vaccine in protecting against SARS-CoV-2 infection and reducing disease severity and hospitalization, little is known about the role lipid nanoparticles (LNP) play in initiating immune response. In this report we studied the adjuvantive impact of empty LNP with no mRNA cargo (eLNP) on anti-viral pathways and immune function of cells from young and aged individuals. We found that eLNP induced maturation of monocyte derived dendritic cells by measuring the expression of CD40, CD80, HLA-DR and production of cytokines including IFN-α,IL-6, IFN-γ, IL-12, and IL-21. Flow cytometry analysis of specific dendritic cell subsets showed that eLNP can induce CD40 expression and cytokine production in cDC1, cDC2 and monocytes. Empty LNP (eLNP) effects on dendritic cells and monocytes coincided with induction pIRF7 and pTBKI, which are both important in mitigating innate immune signaling. Interestingly our data show that in response to eLNP stimulus at 6 and 24 hrs, aged individuals have decreased CD40 expression and reduced IFN- γ output compared to young adults. Furthermore, we show that cDC1, cDC2, and CD14dim CD16+ monocytes from healthy aged individuals have dysregulated anti-viral signaling response to eLNP stimulation as measured by the defect in type I IFN production, phosphorylation of IRF7, TBK-1, and immune function like phagocytosis. These data showed a novel function of eLNP in eliciting DC maturation and innate immune signaling pathways and that some of these functions are impaired in older individuals providing some suggestion of why older individuals (> 65 yrs of age) respond display lower immune responses and adverse events to SARS-CoV-2 mRNA-based vaccines.


Introduction
Two of the current COVID-19 vaccine designs are based on nucleoside-modi ed messenger RNA (mRNA)lipid nanoparticles (LNP). This vaccine platform has been widely tested in preclinical and clinical studies showing its effectiveness in generating protective humoral immunity 1,2,3,4,5 . Additionally, it has been shown that the immune stimulatory effects of the mRNA-LNP vaccine platform is not due to the inclusion of nucleoside modi ed mRNA but by the intrinsic adjuvant effect of the ionizable lipid, a major component of the LNP formulation, which on its own can induce an in ammatory response 1,6 . However, the mechanism of this response has not been fully investigated. Previous studies seeking to elucidate the mechanism of these immunomodulatory agents has identi ed the involvement of different pathogenassociated molecular pattern (PAMP)-sensing receptors and pathways in mice 1, 6, 7 but few, if any, studies exist in humans. Recently, Alameh et. al published that the addition of empty LNP (eLNP) not only intrinsically promoted the secretion of IL-6, among other cytokines in mice, but also induced robust T FH cell responses after immunization. Removal of the ionizable lipid from the LNP abrogated the vaccine response highlighting its essential role in adjuvanticity. Another group recently published that lipidformulated RNA vaccines induce production of IL-1 which then induce pro-in ammatory cytokines like IL-6 8 .

Page 4/17
Although more studies are needed to determine how the LNP is sensed and how pro-in ammatory cytokines and chemokines including IL-6 production are regulated. Age is another factor that can in uence vaccine response. The progressive decline in the function of the immune system with increasing age is a condition known as immunosenescence which not only leads to decreased protection against infectious pathogens but also leads to the inability to mount protective immune responses following vaccination 9 . An age associated decrease in protection against infectious pathogens is demonstrated by the increased mortality rates in individuals above 65 years of age following infection. An increase in mortality in aged individuals was clearly demonstrated during the COVID-19 pandemic where individuals aged 65-74 were upwards of 95 times more likely to die from SARS-CoV-2 infection when compared to the 18-29-year-old population 10 . With the global population over the age of 65 expected to double by the year 2050 11 , it is imperative to gain a deeper understanding of the underlying mechanisms of immunosenescence to effectively protect this portion of the population.
In those over 65 it has been shown that there are de cits in innate antiviral signaling and adaptive immune response to the SARS-CoV-2 vaccine particularly for variants of concern, suggesting that LNP stimulatory effects could be altered in the aged. 12 Many of the recent studies that look at SARS-CoV-2 vaccination in people over 65 show induction of strong humoral responses against the virus, and its variants 13 . Other studies show that coordination of SARS-CoV-2 antigen speci c responses are disrupted in those individuals 14 . The data suggests less of a role for the humoral response than SARS-CoV-2 speci c CD4 + or CD8 + T cells in providing complete protection against severe disease in older adults. Understanding how LNP interacts with the innate immune system, especially within an aging context can help us to continue to develop adjuvants to induce stronger and more durable responses in older individuals.
In this report, we demonstrate that the eLNP formulation used in previous studies in mice 1,2 is effective at maturing monocyte-derived dendritic cells and activating DCs and monocytes from human PBMCs causing secretion of not only innate immune cytokines and chemokines but also pro-T FH cytokines including IL-21 and IL-6 15 . We also demonstrate that there is an age-speci c difference between important innate immune cytokines and chemokines and show that eLNP initiate TGF-β production as a potential mechanism of human T FH cell differentiation 16 . Mechanistically, the capacity of eLNP to elicit robust induction of innate and adaptive responses shows evidence of being dependent on pathways that converge upon TBK-1 (phosphorylation of TBK-1) though differences between younger and older adults was less noticeable. We also show that the addition of eLNP acts as a stimulator of phagocytosis. This study sheds light on the mechanism of the immunomodulatory component of the recent SARS-CoV-2 vaccines and how we can improve vaccine e cacy in the more vulnerable population. Results eLNP treatment promotes robust innate immune response and DC maturation The effect of eLNP on innate immune cells is not fully elucidated in humans. To investigate this, we tested the ability of eLNP to induce DC maturation in vitro. Monocytes isolated from healthy participant PBMCs (n=18; age range 24-75 yrs) were treated with GM-CSF/IL-4 for 48 hrs followed by maturation with a dose of 15 μg/mL (total lipids, or~7.5 μg/mL ionizable lipid) empty LNP (eLNP) for 24 hrs. We assessed the frequency of surface costimulatory and HLA marker-expressing cells in eLNP-treated MDDCs compared to unstimulated cells after 24 hrs. The gating strategy used for MDDCs, and the determination of their surface marker frequencies is shown in Supplemental Figure 1. We found that eLNP signi cantly up-regulated the percentage of CD40-positive human MDDCs compared to unstimulated control (p=0.0043) (Figure 1a). We also see an upregulation in the maturation markers of MDDCs (CD83 (p=0.0001), CD86 (p=0.0114), and HLA-DR (p=0.002) (Supplemental gure 2a and 2b). We also tested the production of cytokines following in vitro DC maturation by eLNP. IL-6 (p=0.0321), IL-12 (p=0.0294), IL-21 (p<0.0001), CD40L (p=0.0009), IFNa (p=0.0040), and IFNg (p=0.0008) signi cantly increased after 24 hrs of eLNP stimulation (Figure 1b). Thus, eLNP can induce pro-T FH cytokines as well as key cytokines and chemokines that are e cient in activating innate immune response like IFNa and IFNg. All together, these data using human MDDCs in our in vitro culture system con rm that eLNP can induce the maturation of human MDDCs and may a play a role in the initiation of innate immunity and a further role in T FH differentiation, function, and proliferation 17 .
We further assess the impact of eLNP on multiple DC and monocyte subsets using multiparametric ow cytometry. Speci cally, we determined the frequency of surface costimulatory marker-expressing cDC1, cDC2, and CD14 monocytes following eLNP treatment of PBMCs ( Figure. 1c). To achieve this, PBMCs were stimulated with eLNP for 24 hrs and then DCs and monocytes subsets were analyzed for the expression of surface marker and cytokine secretion. Conventional type 1 DCs (cDC1) are the primary subset that cross-presents antigen to CD8+ T cells and predominantly produce IL-12 18,19,20,21 . In contrast, conventional type 2 DCs (cDC2) have been associated with CD4+ T FH cell responses including GC T FH responses 17,21,22 . Additionally, we monitored CD14+CD16-, CD14+CD16+ and CD14 dim CD16 + monocytes. The latter plays a vital role in antiviral immunity and response to vaccination by patrolling the vascular endothelium in response to viral exposure and produce TNF-a and IL-1b 23,24 . We found that eLNP induces the expression of CD40 in cDC2 (p<0.0001) and cDC1 (p<0.0001), and CD14 dim CD16 + monocytes (p=0.0004). Additionally, we also see the upregulation of multiple activation markers on monocyte and DC subsets from PBMCS, namely OX40L (cDC2 (p<0.0001), cDC1 (p=0.0174)) (Supplemental gure 3b). We saw no signi cant changes in the other subsets of monocytes (data not shown). We also examined the eLNP-induced cytokine and chemokine pro le of PBMCs. After stimulation with eLNP over 0-,6-, and -24 hrs, the production of cytokines and chemokines was signi cantly elevated consistent with a pro-in ammatory phenotype compared to unstimulated cells, namely IL-6 (p=<0.0001), IL-21 (p<0.0001), IFNg (p<0.0001), and CXCL13 (p=0.0001) (Figure 1d). To further investigate how eLNP might affect a rst line defense, we isolated monocytes (CD14+) from PBMCs and stimulated with eLNP at 0-,6-, and -24 hrs and measured the production of cytokines and chemokines. We found that monocytes had signi cantly increased upregulation of IL-1b (p=0.0132), IL-6 (p=0.0208), and CX3CL1 (p=0.0040) by 6 hr that was sustained through 24 hrs (Figure 1e). The monocyte chemokines MIP1a and MCP-1 were signi cantly upregulated by 24 hrs post stimulation (MIP1α (p<0.0001) and MCP-1 (p<0.0001)). These data con rm that eLNP activates DCs and monocyte subsets and suggest the possibility that eLNP may mediate its effect by activation and maturation of innate immune cells.

IRF7/TBK-1 axis is induced by eLNP
DCs and monocytes help shape the innate immune response via the activation of pattern recognition receptors (PRR) and other molecular sensors. The activation of different TLR (such as TLR 2,4, and 7/8) and RLR pathways initiates a series of cross-talk signaling events that are mediated by TBK-1, which leads to the phosphorylation, dimerization, and translocation of the transcription factor, IRF7 25,26 . We next determined if eLNP can elicit phosphorylation and activation of IRF7 and TBK-1. Human PBMCs from 18 donors were stimulated with a dose of 15 μg/mL (total lipids, or~7.5 μg/mL ionizable lipid) eLNP for 15 min-, 45 min-, 6-, and 24 hrs, and ow cytometry was performed to determine whether eLNP alone can induce and activate IRF7 in DC and monocyte subsets, as measured by phosphorylation of IRF7 (pIRF7). Overall, eLNP treatment was able to notably induce IRF7 activation in cDC2 and cDC1 ( Figure 2). Following a 6-hour stimulation, signi cant upregulation of pIRF7 was observed in cDC2 DCs (p= 0.0022) and was maintained through 24 hrs of stimulation (p= 0.0067) (Figure 2a). Signi cant upregulation of pIRF7 was observed as early as 45 min in cDC1 DCs (p= 0.0009), and this signi cant upregulation was enhanced and then maintained for both the 6-and 24-hour stimulations, respectively (6 hr p= <0.0001; 24 hr p= <0.0001). In addition to the phosphorylation of IRF7, we also saw phosphorylation of TBK-1 (pTBK-1) after eLNP stimulation in both cDC1 and cDC2 DCs ( Figure 2b). Here, we saw a signi cant upregulation of pTBK-1 following a 6-hour stimulation in both cDC2 (p=0.0052) and cDC1(p<0.0001) DCs. These increased levels of pTBK-1 were maintained through a 24-hour stimulation for both DC subsets (cCD2, p= 0.0067; cDC1, p= <0.0001). We did not see a signi cant difference in pIRF7 or pTBK-1 induction in CD14 dim monocytes (Supplemental gure 4). Overall, these results demonstrate that eLNP can activate IRF and TBK-1 signaling pathways.
Phagocytosis is induced in cDC2, cDC1 in response to eLNP stimulation.
A primary function of innate immune cells is phagocytosis. Here, we investigated whether eLNP can induce phagocytosis in antigen presenting cells utilizing an in vitro phagocytosis assay which measures the uptake of uorescent beads. We stimulated healthy adult PBMCs with eLNP for 24 hrs and ow cytometry was performed to analyze the MFI of engulfed particles as a function of phagocytosis of DC subsets and CD14 dim monocytes. Upon stimulation with eLNP, cDC2, cDC1 subsets show increased uorescence (cDC2, p<0.0001; cDC1, p<0.0001) compared to unstimulated indicating superior phagocytic function following stimulation with eLNP ( Figure 3a-b). CD14 dim monocytes show increased uorescence when stimulated indicating greater activation (p<0.01) (Figure 3b). eLNP elicits TGF-β production in PBMCs and MDDCs TGF-β has previously been shown to play essential roles in the differentiation and function of T cells, inhibiting the differentiation of Th1 and Th2 T cells 27 while promoting Treg, Th17, and T FH differentiation 27,28 . To test whether eLNP treatment leads to production of TGF-β isoforms (TGF-β1, TGF-β2, and TGF-β3) within innate immune cells, PBMCs were treated for 6 or 24 hrs with eLNP (15 μg/μL-1 total lipids, or 7.5 μg/μL-1ionizable lipid) and compared to both unstimulated cells. The levels of TGF-b1 in PBMCs were induced after 24 hrs of stimulation (p= <0.0001) while the levels of TGF-b3 were induced starting at 6 hrs (p= 0.0011) and increased when measured after 24 hrs of stimulation (p= <0.0001) ( Figure 4a). Similarly, MDDCs from donors were treated for 24 hrs with eLNP and compared to unstimulated cells. Interestingly, TGFb2 levels were downregulated upon stimulation with eLNP for 24 hrs in MDDCs (p= 0.0065) suggesting a differential role between cell types (supplemental gure 5a).

eLNP alter MDDC maturation and cytokine secretion in younger and older adults
After establishing that eLNP can induce an immune response, we aimed to describe how eLNP would affect an aged immune system. Therefore, we strati ed our 18 subjects as young and old. Our old volunteers are healthy, non-frail individuals enrolled into the study are accrued with an equal sex distribution. Individuals with comorbid conditions like cancer within the last 5 years, or other immunocompromising conditions, and steroid use were excluded. Inclusion criteria included controlled hypertension, occasional aching joints from arthritis and not taking daily nonsteroidal anti-in ammatory drugs or acetaminophen, and controlled diabetes. The average age for adults was 30 years (range 24-36 years) whereas for older group it was 73 years (range 67-83 years) (Supplemental Table 1). Utilizing our cohort of 9 younger adults (<65) and 9 older adults (>65) we analyzed the effect of eLNP on the maturation and activation of the innate immune system. There were no signi cant differences in frequencies of cell types between eLNP stimulated cells from older or younger donors (data not shown). We found that eLNP signi cantly up-regulated the percentage of CD40-and CD83-positive human MDDC compared to unstimulated control (young, p=0.0079; old, p=0.0478) ( Figure. 5a-d) for both older and younger participants. Speci cally, the increase in eLNP-mediated CD83 expression was noted to be signi cantly different in older and younger participants (p= 0.0041) (Figure 5a). Empty LNP induced the expression of CD40 (Figure 5a) in both younger (p= 0.0006) and older participants, which is known to be important for human T FH helper function via CD40L engagement. However, intergroup comparison showed that CD40 expression was higher for younger participants but did not reach statistical signi cance (p= 0.0939) (Figure 5a). We also examined the eLNP-induced cytokine and chemokine pro le of MDDCs within this aged cohort. Empty LNP administration signi cantly increased the secretion of CD40L (young=0.0939, old p=0.0086), IL-2 (young=0.0015, old p=0.0031), and IL-12 (old p=0.0151) ( Figure 5b). Namely, we saw signi cantly more cytokine production in older vs younger adults in CD40L (p=0.0061), IL-2 (p=0.0515), and IL12p70 (p=0.0376). Overall, our results show that eLNP can induce the maturation of MDDCs in vitro in both young and old individuals, however maturation markers are signi cantly lower in older subjects whereas pro-in ammatory cytokines are higher.
eLNP induces age-speci c activation in cDC1, cDC2, and CD14 dim CD16 + monocytes from PBMCs To determine the effect that eLNP has on the activation of monocyte and DC subsets between age groups, PBMCs from healthy young or older participant were treated with either eLNP for 6 or 24 hrs. We assessed the frequency of surface costimulatory marker-expressing cells in eLNP-treated PBMCs compared to unstimulated cells after 24 hrs (Figure 5c). 41BBL is expressed on antigen-presenting cells that, upon ligation to its cognate receptors, activates both CD4 and CD8 T cells and induces their proliferation 29,30 . We found that that 41BBL was upregulated with eLNP stimulation in cDC2 (p=0.0283) and cDC1 (p=0.0090) of younger donors. We also see an age speci c difference between young and older participants in cDC2 when stimulated with eLNP (p=0.0019) and a trend in cDC1 (p=0.0977). We also observed a signi cant upregulation in the expression of CD40 due to eLNP stimulation in the same cell types cDC1 (young, p<0.0001; old, p=0.0004) and cDC2 (young, p<0.0001; old, p<0.0001). PD-L1 engagement limits the proliferation of antigen-speci c T cells in the germinal center by binding to activated T cells, B cells, and other myeloid cells. We found that in response to eLNP stimulation, only cDC2 (p=0.0002), cDC1 (p=0.0007), and CD14 dim CD16 + monocytes (p=0.0055) from older donors upregulated PD-L1 (Figure 5c).
eLNP stimulation results in impairment of phagocytosis in CD14 dim CD16 + monocytes in older adults Upon stimulation with eLNP, all subtypes of monocytes and DCs showed increased phagocytosis in both young and older adults (Figure 6a-b). Although eLNP enhanced the phagocytic ability of monocyte and DC subsets in all individuals, monocyte subtypes in aged individuals had reduced phagocytic activity (Figure 6b).
In DC subsets, there was no signi cant difference in phagocytosis between young and older adults in response to stimuli, but phagocytosis was induced in cDC2 (young: eLNP, p=<0.0001; old: eLNP, p= <0.0001) and cDC1 (young: eLNP, p=<0.0001; old: eLNP, p=<0.0001). Empty LNP was capable of inducing phagocytosis in younger adults in CD14 dim CD16 + with eLNP (p=0.0010). CD14 dim CD16 + from older adults had signi cant decrease in phagocytosis compared to younger adults when stimulated with eLNP (p=0.0106). Of note, cDC2 showed signi cant decrease in phagocytic ability in older adults in LPS/IFN-g levels (p=0.0091), which predicts that cDC2's role in T cell differentiation and GC reaction might also signi cantly impaired in older adults (Supplemental gure 5a). This impairment was easily rescued when induced with eLNP and had similar amount of phagocytic function throughout the DC subsets, which further underscore the ability of eLNP to enhance phagocytosis.
eLNP mediates differential production of TGF-β production between younger and older adults To further understand the age differences following eLNP stimulation, TGF-β production by MDDCs and PBMCs from young and old participants was explored. For MDDCs, differences in TGF-β2 production were observed between young and old in immature cells (p=0.0232) (Figure 7a). However, following a 24hour treatment with eLNP, TGF-β2 production by MDDCs from young individuals was signi cantly lower than that found in older healthy adults (p=0.0005) (Figure 7a). Additionally, eLNP treatment led to a reduction in the production of all isoforms of TGF-β in aged individuals compared to levels detected from unstimulated MDDCs in the same aged individuals. In contrast, TGF-β production by MDDCs from young individuals was not found to be altered when compared to unstimulated MDDCs from the same young participants.
To gain a better understanding of the ability of eLNP treatment to initiate TGF-β production, PBMCs isolated from both healthy young and aged participants were treated with eLNP for either 6 or 24 hrs (Figure 7b). Although no signi cant differences were initially observed between stimulated and unstimulated cells after 6 hrs in TGF-β1 and TGF-β2, TGF-β3 levels were signi cantly higher in both young (p p<0.0001) and older participants (p p<0.0001). TGF-β1 (young, p=0.0034; old, p<0.0001) and TGF-β3 (young, p=0.0004; old, p=0.0022) showed signi cant expression in both young and older adults after 24 hrs stimulation with eLNP. Importantly, other than TGF-β2 at 24-hour stimulation (p=0.0737), TGF-β1 production in young participants was reduced compared to old at 24 hrs (p=0.0047) (Figure 7b). Altogether, these data suggest that eLNP treatment is a potent inducer of TGF-β production in PBMCs while also suggesting that there are age-associated differences in the ability of eLNP to stimulate TGF-β production in young vs aged healthy adults. The ability of eLNP to induce TGF-β production and the differences observed between young and aged adults in the level of TGF-β that is induced are likely of importance, particularly in the use of eLNP during vaccination, due to the essential roles that TGF-β plays in the differentiation and function of T cells.

Discussion
Aging is associated with increased morbidity and mortality to viral infections including SARS-CoV-2 31 . Of the multiple factors that contribute to this, impaired vaccine responsiveness and the creation of immunological memory are key contributors. To continue to identify vaccine platforms and adjuvants that strongly promote immune responses in older adults is critically important. Recently, modi ed nucleoside mRNA vaccines were approved to control the ongoing pandemic caused by SARS-CoV-2 (COVID-19). These vaccines utilize LNP containing ionizable lipids, that have been shown to potently induce IL-6 secretion and T FH and GC B cell generation in humans 1,32,33,34 . It is worth noting that while LNP have been used in many different mRNA vaccine platforms, several studies have investigated the adjuvant effect. However, differences in LNP formulations and study design make it di cult to compare and correlate ndings. As more mRNA-LNP vaccines are being designed for other infectious diseases, studies investigating the mechanism of immune modulation including the effect of LNP on innate immunity are critical to improve the e cacy of vaccines in older populations.
In this study, we expand upon the mechanism of ionizable eLNP formulation that Alameh et. al. previously investigated. It was previously reported that the adjuvant properties of this LNP formulation are linked to the ionizable lipid component of LNP and that there is an intrinsic ability of the eLNP to promote IL-6 secretion in mice and subsequent T FH induction. We show that eLNP formulation induces the maturation and activation of DCs and monocytes as measured by the frequency of co-stimulatory surface receptors and the production of cytokines and chemokines (Fig. 1). We also show that there are age-speci c differences in the maturation and activation in both MDDCs and subsets from PBMCs, namely cDC1, cDC2, and CD14 dim CD16 + monocytes (Fig. 5). This suggests the possibility that eLNP may mediate its effect on germinal center formation and T FH function at least in part, by altering the maturation status of antigen-presenting cells 1 . While Alameh et al show that the adjuvant effect of eLNP is maintained in MyD88-and MAVS-de cient mice, in human PBMCs, we show that eLNP treatment can induce the phosphorylation of IRF7 and TBK-1 (Fig. 2), key signaling molecules in antiviral signaling pathways potentially indicating signaling endosomally through other TLRs (e.g., TLR2, TLR3 and TLR4). TBK-1 induces innate antiviral type I IFNs but also plays a much broader role in antibody formation and autophagy 35,36 . More recent studies have shown that TBK-1 associates with ICOS and plays a role in the differentiation of GC T FH cells and the development of B cell responses 37 . Consequences of decreased TBK-1 activity in cDC2 due to aging in response to eLNP (Fig. 2b) 39 . Upon 6 hr eLNP transfection, this group did not see an elevated ISG score nor an induction of TBK-1 transcripts in healthy controls. This difference in results obtained could be due to several factors: 1) whole blood vs the use of isolated PBMCs and puri ed DCs as the cell populations of interest in our study are infrequent in whole blood; 2) our study looked at phosphorylation of IRF7 and TBK-1 and protein levels of cytokine and chemokine and not on transcript expression.
Importantly, we have found that in response to eLNP treatment, cDC2, cDC1, and CD14 dim CD16 + monocytes from older donors have upregulated PD-L1 when compared to younger counterparts (Fig. 5c). PD-L1, through virtue of its function, regulates the germinal center response by limiting T FH differentiation and function 40 . However, the upregulation of PD-L1 on cDCs is a critical role to protect against killing of cytotoxic T lymphocytes (CTLs), errant PD-L1 expression might contribute to the decrease in immune responsiveness in older adults.
To investigate the mechanism of eLNP as a regulator of T FH differentiation and innate immunity, we evaluated TGF-β production. TGF-β is a potent modulator of proliferation, differentiation, and function of all of lymphocytes, dendritic cells, and macrophages, essentially regulating both innate and antigenspeci c immunity. In monocytes and DCs, TGF-β1 is mostly suppressive through inhibition of cell proliferation and reduction of reactive oxygen and nitrogen species 41 . TGF-β1 also acts as a chemotactic factor and can induce migration in monocytes and can suppress the type I IFN response in alveolar macrophages 42,43 . We show that TGF-βexpression was signi cantly increased following eLNP stimulation in PBMCs from older individuals. In contrast, TGF-β expression in MDDCs was reduced in younger individuals therefore maintain the imbalance between old vs young upon eLNP stimulation (Fig. 7a). However, at 24 hrs stimulation with eLNP, PBMCs from older adults signi cantly increase production of TGF-β1 when compared with their younger counterparts. Increased TGF-β1 production by these cells might play a role in the overall decreased antiviral and vaccination response. Coupled with our nding that the addition of eLNP signi cantly increases the ability of cDC2 and cDC1 from younger and older donors to phagocytose, there is an evident role of eLNP in modulating vaccine responsiveness. In fact, cDC2 show a signi cant decrease in phagocytic ability when stimulated with LPS/IFN-γ in older donors (Supplemental Fig. 6). That age-speci c difference is rescued when stimulated with eLNP, bringing levels of phagocytosis to that of younger donors indicating that eLNP can potentially be enhancing overall phagocytosis. TGF-β signals through STAT3:STAT4 to promote the differentiation of T FH cells 16 however the molecule also plays a role in the differentiation of T helper 17 (Th17) cells in in ammatory conditions in the presence of IL-6. We show an induction of IL-6 in PBMCs when stimulated with eLNP in both younger and older donors (Fig. 5) suggesting multiple roles of TGF-β under eLNP stimulation.
A recent study showed that after vaccination with two doses of P zer-BioNTech mRNA vaccine (BNT162b2), pSTAT 1 and pSTAT3 was increased as well as the anti-in ammatory cytokine IL-10 further con rming a role for eLNP in initiating these responses 44 . We also show that in response to eLNP, IL-12 and IL-21 is secreted by MDDCs from older donors (Fig. 5b) and PBMCs from older and younger donors (Fig. 5d) suggesting a pro-T FH inducing environment further indicating that eLNP is playing critical roles during vaccination 15 . We believe that our study provides important insight into the mechanism of action of eLNP such as those used in the P zer and Moderna COVID-19 vaccines.

Experimental Methods
Human Samples: Blood samples were obtained from healthy donors at Martin Memorial Health Systems (Florida). Consenting adults were screened using a questionnaire determining their demographic information, medication usage, and comorbidities. Participants were excluded with any acquired immunode ciency or immunomodulating medications (such as steroids or chemotherapy), pregnancy, history of cancer, and history of cirrhosis or renal failure, or antibiotic use within 2 weeks of recruitment. Blood samples were taken from individuals aged 18-80 and were made into single cell PBMC suspensions and frozen in bovine serum albumin (Sigma) plus 10% DMSO (VWR) for cryopreservation in liquid nitrogen. The Institutional Review Boards at the relevant institutions approved all procedures, and all participants provided signed informed consent.

Empty LNP generation
The LNP formulation used in this study is proprietary to Acuitas Therapeutics; the proprietary lipid and LNP composition are described in US patent US10,221,127. Brie y, an ethanolic lipid mixture of a proprietary ionizable lipid, DSPC, cholesterol, and polyethylene glycol-lipid was rapidly mixed with an acidic aqueous solution (PMID: 23799535 45 ), dialyzed, concentrated, frozen and stored at -80 °C. Empty LNP were formulated at an equivalent mRNA concentration of 1 mg/ml and total lipid concentration of 30 mg/ml 11 . The mean hydrodynamic diameter of eLNP, measured by dynamic light scattering using a Zetasizer nano ZS (Malvern) was ~80 nm with a polydispersity index of 0.02-0.06.

Determining Optimal Dose of eLNP
PBMCs were stimulated with eLNP in a twofold dilution to determine optimal dose. Optimal concentrations of eLNP were selected based on median production of IFN-g and an 85% or more survival rate (Supplemental gure 7). In vitro phagocytosis assay: PBMCs from healthy young and older donors were plated at a volume of 1.0 x 10 6 cells per well in a round 96-well plate in a volume of 100 µl of complete RPMI medium at 37°C and at 4°C as a negative control. PBMCs were then stimulated as stated above for 24 hrs. After a 24 hour stimulation period, cells were washed twice with FACS buffer to remove agonist and incubated with 0.04 µm uorescent microspheres (Invitrogen, Cat: F8794) for 3 hrs. The cells were then washed twice with FACS buffer to remove any beads from the outside of the cell and prepared for ow cytometry.
Phagocytic ow cytometry analysis of monocyte and DC subsets: The PBMCs from adult or older adult donors were prepared and incubated with uorochrome-conjugated antibodies for ow cytometry. Brie y, after stimulation, cells were washed twice with FACS buffer, surface stained using antibodies for 30 minutes in 100 µl of FACS buffer, and then xed using 2% PFA for 15 minutes at 37°C. Cells were phenotyped as stated above.
Cytokine and chemokine analysis: Supernatants collected from PBMCs during stimulation were analyzed for chemokine/cytokine levels using the human immune monitoring 65-Plex ProcartaPlex™ Panel (Invitrogen™). This kit was used to determine the levels of 65 cytokines, chemokines, growth factors, and soluble receptors produced by MDDCs, 24 hrs after stimulations, and PBMCs 6 and 24 hrs after (CD154), IL-2R (CD25), TNF-RII, TRAIL (CD253), TWEAK. Data was acquired on a Luminex™ FLEXMAP 3D™ System using bead regions de ned in the protocol and analyzed using Belysa Curve Fitting Software (Sigma Aldrich). Standard curves were generated, and sample concentrations were calculated in pg/mL. Statistics: All ow cytometry, Luminex, and confocal data were analyzed using GraphPad Prism v9.
Where appropriate, stimulations were subtracted from their background controls, i.e., LPS/IFNg stimulated cells were subtracted from unstimulated, RIG-I agonist was subtracted from LyoVec only control, and G10 STING agonist was subtracted from a DMSO control. Unpaired, non-parametric Mann Whitney test was used when comparing two groups. The Paired multiple t-test and non-parametric oneway ANOVA (Friedman) test was used when comparing more than two groups to each other. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Declarations
Author Contributions JRC designed and performed experiments, analyzed results, and interpreted data; GC performed MDDC isolation and ow cytometry; DJ and NM performed and analyzed monocyte Luminex and ow cytometry experiments; MRB, JM, BT assisted with writing of the paper; KK performed ELISA assay and ow cytometry; MK and MGA provided productive discussions; PL and YT provided lipid nanoparticles. MGA and DW originated LNP experiments and provided empty LNP materials; JRC, MGA and EKH conceived, designed experiments, brought original ideas, and wrote the paper with the help of co-authors. EKH implemented and directed the study. All co-authors have read, edited, and commented on the paper.